Literature DB >> 33685220

Transradial Versus Transfemoral Access for Percutaneous Coronary Intervention in ST-Segment-Elevation Myocardial Infarction: A Systematic Review and Meta-Analysis.

Pietro Di Santo1,2,3, Trevor Simard1,3,4, George A Wells5,2,3, Richard G Jung1,3,4, F Daniel Ramirez1,6,7, Paul Boland1,3, Jeffrey A Marbach1,3, Simon Parlow1,3, Kwadwo Kyeremanteng3,8, Doug Coyle2,3, Dean Fergusson2, Juan J Russo1,3, Aun-Yeong Chong1,3, Michael Froeschl1,3, Derek Y So1,3, Alexander Dick1,3, Christopher Glover1,3, Marino Labinaz1,3, Benjamin Hibbert1,3,4, Michel Le May1,3.   

Abstract

[Figure: see text].

Entities:  

Keywords:  ST-segment–elevation myocardial infarction; acute coronary syndrome; coronary angiography; glycoprotein; percutaneous coronary intervention

Year:  2021        PMID： 33685220     DOI： 10.1161/CIRCINTERVENTIONS.120.009994

Source DB:  PubMed          Journal:  Circ Cardiovasc Interv        ISSN： 1941-7640            Impact factor:   6.546


  3 in total

1.  State-of-the-Art Endovascular Therapies for the Femoropopliteal Segment: Are We There Yet?

Authors:  Ramya C Mosarla; Ehrin Armstrong; Yonatan Bitton-Faiwiszewski; Peter A Schneider; Eric A Secemsky
Journal:  J Soc Cardiovasc Angiogr Interv       Date:  2022-08-20

2.  Trends in Ischemic Mitral Regurgitation Following ST-Elevation Myocardial Infarction Over a 20-Year Period.

Authors:  Leor Perl; Tamir Bental; Katia Orvin; Hana Vaknin-Assa; Gabriel Greenberg; Pablo Codner; Yaron Shapira; Mordehay Vaturi; Alexander Sagie; Ran Kornowski
Journal:  Front Cardiovasc Med       Date:  2022-01-13

3.  Transradial versus Transfemoral Access and the Risk of Acute Kidney Injury following Primary Percutaneous Coronary Intervention in Patients with ST-Elevation Myocardial Infarction: A Systematic Review and Meta-Analysis of Randomized Controlled Trials and Propensity-Score-Matched Studies.

Authors:  Gaspar Del Rio-Pertuz; Michel Juarez; Poemlarp Mekraksakit; Kanak Parmar; Mohammad M Ansari
Journal:  J Interv Cardiol       Date:  2022-03-10       Impact factor: 2.279
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.